Company Overview

Update
Founders:
Christopher K. Mirabelli, Daniel Ripley
Headquarters:
Carlsbad, CA
IPO:
Went Public on May 24, 1991
Stock:
NASDAQ:ISIS
Categories:
Biotechnology

Isis Pharmaceuticals develops novel drugs for the treatment of cardiovascular, metabolic, severe and rare diseases.

Description

Update

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO™, in the United States and Europe following regulatory approval. Isis' patents provide strong and extensive protection for its drugs and technology.

Current Team (9)

Update

Board Members and Advisors (7)

Update

Funding Rounds (1) - $201.30M

Update

Offices/Locations (1)

Update
  • Office

    2855 Gazelle Court

    Carlsbad, CA 92010

    USA

Images (1)

Update
  • 338a6284df3cccb8a239c8b4455471d1